Genetic markers predictive of response to glatiramer acetate

摘要

The present invention provides a method for treating a human subject afflicted with multiple sclerosis or a single clinical attack consistent with multiple sclerosis with a pharmaceutical composition comprising glatiramer acetate and a pharmaceutically acceptable carrier, comprising the steps of: (i) determining a genotype corresponding to the nucleotide polymorphisms consisting of: Group 1, of the subject at a location location of one or more single (SNPs) selected from the group.